Ella Toh

Senior Analyst

Ella has a clear understanding of systematic literature reviews, network meta-analyses, and secondary research, with a strong interest in oncology.

At PRMA Consulting, she has been involved in targeted literature reviews and disease area reviews, value stories, and PRMA Healthchecks®, in the areas of ovarian cancer, hepatocellular carcinoma, upper gastrointestinal carcinoma, major depressive disorder, Crohn’s disease, and infectious disease.

She has an MSc in Economic Evaluation in Healthcare from the University of London, and an MPharm from the University of Strathclyde, Glasgow (twinning program in collaboration with International Medical University Malaysia).

Ella speaks fluent Malay, with conversational Mandarin and Cantonese.

Outside of work, Ella spends her time with her young family and, when possible, spends time in the kitchen cooking and baking for friends and family.

The insights you need to get the inside edge

Driving BioPharma Access in Europe: Insights for Markets Outside of EU5  

Welcoming Lewis Ruff, Senior Director, Global HEOR, within our policy, access, value, and evidence capability

Adapting to Change: Strategies for Pharma Service Providers, CROs, and R&D Partnerships in the Era of the Inflation Reduction Act

Forecasting global value assessments for a rare-disease drug

Welcoming Tyler Piazza, Partnerships Director, HEOR and hēRo3, within our policy, access, value, and evidence capability

Welcoming Caroline Solon, Senior Director Global Market Access, within our policy, access, value, and evidence capability

Cross-functional integrated evidence generation planning for a therapy treating ANCA‑associated vasculitis (AAV)

Digital therapeutics: policy, access, value, and evidence

The hēRo3 Revolution: Accelerating and Empowering HEOR Analytics with Cutting-Edge Digital Solutions

Value, Evidence, and Access: insights for markets outside of the EU5